Report on hearing loss in oncology Classificações das perdas auditivas em Oncologia

Report on hearing loss in oncology Classificações das perdas auditivas em Oncologia

Cisplatin is used frequently as an antineoplastic drug in the treatment of many different cancers. However, when used in doses over 360mg/m², ototoxicity may ensue, resulting in loss of hearing. Criteria for identifying and quantifying hearing loss have been devised. AIM: To describe the features of...

Full description

Bibliographic Details
Main Authors: Christiane Schultz, Maria Valéria Schmidt Goffi-Gomez, Patrícia Helena Pecora Liberman, André Lopes Carvalho
Format: Article
Language:English
Published: Elsevier 2009-10-01
Series:Brazilian Journal of Otorhinolaryngology
Subjects:
cisplatino
oncologia
perda auditiva
quimioterapia
cisplatin
oncology
hearing loss
chemotherapy
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942009000500004

Similar Items

Similar Items